research use only
Cat.No.S7319
| Related Targets | CDK HSP PD-1/PD-L1 ROCK Wee1 DNA/RNA Synthesis Microtubule Associated Ras KRas Aurora Kinase |
|---|---|
| Other Rho Inhibitors | NSC 23766 Trihydrochloride CCG-1423 ML141 (CID-2950007) EHT 1864 2HCl ZCL278 MBQ-167 CCG-203971 CID44216842 1A-116 Rhosin hydrochloride |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| human MDA-MB-435 cells | Function assay | 24 h | Inhibition of Rac1 in human MDA-MB-435 cells after 24 hrs by G-LISA assay, IC50=1.1 μM | |||
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 86 mg/mL
(199.74 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 430.55 | Formula | C25H30N6O |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1380432-32-5 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CCN1C2=C(C=C(C=C2)NC3=NC(=NC=C3)NCCCN4CCOCC4)C5=CC=CC=C51 | ||
| Targets/IC50/Ki |
Rac1
(MDA-MB-435, MDA-MB-231 cells) 1.1 μM
|
|---|---|
| In vitro |
Rac inhibition by EHop-016 increases the activity of the closely related Rho GTPase RhoA by a compensatory mechanism. In MDA-MB-435 cells, this compound (2-5 μM) inhibits association of active Vav2 with Rac1(G15A) mutant fusion protein, and reduces Rac-regulated cell functions including lamellipodia formation and cell migration. In addition, it inhibits cell viability of MDA-MB-435 cells with IC50 of 10 μM. This chemical also inhibits KITD814V-induced growth in SM and AML patients-derived cells. |
| Kinase Assay |
Rac Activity Assays
|
|
Rac activity is determined from lysates of the MDA-MB-435 and MDA-MB-231 human metastatic cancer cell lines. Cancer cells in culture medium (DMEM, 10% FBS, pH 7.5) are treated with vehicle (0.1% DMSO) or varying concentrations of EHop-016 (0–10 μM) for 24 h. Rac1 activity is determined using the G-LISA Rac1 activation assay kit.
|
|
| In vivo |
Treatment of KITD814V-bearing cells with EHop-016 significantly enhances the survival of leukemic mice. |
References |
|
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Western blot | p-AKT / AKT / p-JNK / JNK Rac1 |
|
25389450 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.